Clinical trials: Ulcerative Colitis in Histologic Remission, open to volunteers
Ulcerative Colitis in Histologic Remission
Association Between LRG and Histologic Remission in Ulcerative Colitis
We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which can predict histologic remission in ulcerative colitis patients in this study.
- Trial name
- NCT06372613
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Showa Inan General Hospital
Ulcerative Colitis (UC)
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
The goal of this study is to better understand treatment strategies for people with ulcerative colitis (UC). Researchers will compare patients with UC in histologic remission (no evidence of inflammation or active disease on…
- Trial name
- NCT06693310
- Testing
- de-escalation or discontinuation of therapy, continuation of current therapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Chicago
Crohn Disease (CD), Ulcerative Colitis (UC)
Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context
Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.
- Trial name
- LEADER (NCT07621783)
- Testing
- Leucine-rich α2-glycoprotein
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Imelda GI Clinical Research Center